ORAGENICS INC
For the period ended Mar 31, 2025. Filed May 9, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 9, 2025
OGEN$0.35+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
| March 31, 2025 | December 31, 2024 | |
|---|---|---|
| (Unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $3,421,078 | $864,840 |
| Prepaid expenses and other current assets | 448,033 | 607,670 |
| Total current assets | 3,869,111 | 1,472,510 |
| Total assets | $3,869,111 | $1,472,510 |
| Liabilities and Shareholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable and accrued expenses | $1,177,038 | $1,355,867 |
| Short-term notes payable, net of debt issuance costs | 2,554,385 | 328,528 |
| Total liabilities | 3,731,423 | 1,684,395 |
| Shareholders’ equity (deficit): | ||
| Preferred stock, no par value; 50,000,000 shares authorized; 7,488,692 and 7,488,692 Series F shares and 1,000,000 and -0- Series G outstanding at March 31, 2025 and December 31, 2024, respectively | - | - |
| Common stock, $0.001 par value; 350,000,000 shares authorized and 21,475,289 and 12,570,100 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | 21,475 | 12,570 |
| Additional paid-in capital | 219,119,378 | 216,561,717 |
| Accumulated deficit | (219,003,165) | (216,786,172) |
| Total shareholders’ equity (deficit) | 137,688 | (211,885) |
| Total liabilities and shareholders’ equity (deficit) | $3,869,111 | $1,472,510 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.